Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03657745 · ClinicalTrials.gov registry record
Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Alzheimer's Light.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT03657745: Recruiting study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Alzheimer's Light.
NCT03657745 is a study of Alzheimer Disease and Mild Cognitive Impairment that is actively recruiting participants, run by Alzheimer's Light. The registered enrollment target is 2,000 participants, below the 2,744-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03657745, a study of Alzheimer Disease and Mild Cognitive Impairment, is actively recruiting participants, sponsored by Alzheimer's Light.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLife https://www.alz.life/) that delivers light therapy at 40 Hz combined with cognitive therapy to improve cognition, function, and quality of life in Alzheimer's disease.
Primary Outcome
The cognitive therapy delivered by ALZLIFE consist of cognitive games: Sudoku, Tic-Tac-Toe, Analog clock comparison, etc. The changes in performance score in these cognitive games are used to calculate the participant's Cognitive Index. Cognitive Index maximum score = 100. The lower score indicates worse performance.
Conditions Studied
Interventions
- DEVICE Combination of 40Hz light and cognitive therapy (ALZLIFE)
Study Locations (1)
Florida
- Andrey Vyshedskiy - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2029-12-31 |
What NCT03657745 shows while recruiting
NCT03657745 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, below the 2,744-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (27% lower).
The record links to 6 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Combination of 40Hz light and cognitive therapy (ALZLIFE) is the first listed.
NCT03657745 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03657745 about?
NCT03657745 is a clinical study titled "Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy". Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per seco...
What is the current status of trial NCT03657745?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2018-01-01. Estimated completion is 2029-12-31.
What conditions does trial NCT03657745 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Deterioration.
What interventions are being tested in trial NCT03657745?
The interventions under investigation include: Combination of 40Hz light and cognitive therapy (ALZLIFE) (DEVICE).
Who is sponsoring clinical trial NCT03657745?
This trial is sponsored by Alzheimer's Light, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03657745 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03657745's enrollment target sits among peer trials
2,000 20th of 306 higher than 286 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI